drugset / Trial / NCT07448324
Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, single-arm, phase II study aimed at evaluating the safety and efficacy of orelabrutinib combined with rituximab ± lenalidomide in response-adapted stratified therapy for untreated marginal zone lymphoma. The primary endpoint is the complete response rate (CRR).
Timeline
- Start
- 2025-04-01
- Primary completion
- 2028-01-01
- Completion
- 2030-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenalidomide | Other / unclassified | — | — |
| Subject | Orelabrutinib | Small molecule | 150 mg | — |
| Subject | Rituximab | Monoclonal antibody | — | — |